{"organizations": [], "uuid": "bc359efb897105e464e701a63ce0b5adfdd0d3a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cynata-therapeutics-says-fda-grant/brief-cynata-therapeutics-says-fda-grants-orphan-drug-designation-to-cymerus-msc-product-cyp-001-idUSASC09TYE", "country": "US", "domain_rank": 408, "title": "BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T15:17:00.000+03:00", "replies_count": 0, "uuid": "bc359efb897105e464e701a63ce0b5adfdd0d3a1"}, "author": "", "url": "https://www.reuters.com/article/brief-cynata-therapeutics-says-fda-grant/brief-cynata-therapeutics-says-fda-grants-orphan-drug-designation-to-cymerus-msc-product-cyp-001-idUSASC09TYE", "ord_in_thread": 0, "title": "BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001", "locations": [], "entities": {"persons": [{"name": "cynata", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-cynata therapeutics", "sentiment": "negative"}, {"name": "reuters staff    cynata therapeutics ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28, 2018 / 12:20 PM / in a minute BRIEF-Cynata Therapeutics says FDA Grants orphan drug designation to cymerus msc product, cyp-001 Reuters Staff \nMarch 28 (Reuters) - Cynata Therapeutics Ltd: \n* FDA GRANTS ORPHAN DRUG DESIGNATION TO CYNATA’S LEAD CYMERUS™ MSC PRODUCT, CYP-001 \n* CYNATA THERAPEUTICS - U.S. FDA GRANTED CO ORPHAN DRUG DESIGNATION FOR CYP-001 FOR TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T15:17:00.000+03:00", "crawled": "2018-03-28T15:34:32.004+03:00", "highlightTitle": ""}